Clinical trials: Second-Line
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia - Chronic Phase
Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines
The goal of this observational study is to evaluate the efficacy and tolerability of asciminib in real-life in patients with chronic myeloid leukemia treated in second or subsequent lines.
- Trial name
- ASCIRLI (NCT07640750)
- Volunteers
- 98 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Ovarian Cancer
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
This is a single arm phase II study with a combination of Hycamptin® (topotecan) and erlotinib for a minimum of 2 cycles in patients (18 yrs of age and older) with recurrent ovarian cancer previously treated with chemotherapy…
- Trial name
- NCT01003938
- Testing
- Topotecan, Erlotinib
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- NYU Langone Health
High Grade Ovarian Cancer, Primary Peritoneal Cancer
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade…
- Conditions
- High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT05456685
- Testing
- Mirvetuximab soravtansine, Carboplatin
- Where
- 69 sites in United States, Belgium and 4 more
- Volunteers
- 125 people
- Sponsor
- AbbVie
Carcinoma, Non-Small-Cell Lung
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
This study involves treatment with KD019 or erlotinib in patients with Non-small cell lung cancer (NSCLC) who have progressed after first- or second- line chemotherapy.
- Trial name
- NCT01487174
- Testing
- KD019, Erlotinib
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Kadmon Corporation, LLC
Breast Neoplasm Female
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
Given the uncertain benefit in efficacy of adding CDK 4/6 to first rather than second line endocrine treatment, the aim of this project is to evaluate whether the sequence of an aromatase inhibitor plus CDK 4/6 in first line…
- Trial name
- NCT03425838
- Testing
- CDK 4/6 inhibitor, Non-Steroidal Aromatase Inhibitor, Fulvestrant
- Where
- 72 sites in Netherlands
- Volunteers
- 1,050 people
- Sponsor
- Borstkanker Onderzoek Groep
Intrahepatic Cholangiocarcinoma
A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma
The propose of this study is to confirm safety and efficacy of Apatinib monotherapy in patients with advanced cholangiocarcinoma.
- Trial name
- NCT03521219
- Testing
- Apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Advanced or Metastatic CRC
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer
To assess the effectiveness and safety of utidelone injection in patients with advanced or metastatic colorectal cancer (CRC) as a phase II trial
- Trial name
- NCT03906565
- Testing
- utidelone injection
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Stage IV Esophagus Squamous Cell Carcinoma
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
To observe and evaluate the efficacy and safety of camrelizumab combined with chemotherapy or anlotinib in patients with advanced esophageal squamous cell carcinoma previously Treated With First-line Immunotherapy
- Trial name
- NCT05322499
- Testing
- Camrelizumab, Irinotecan, Paclitaxel
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhejiang Cancer Hospital
Colorectal Cancer, Colorectal Carcinoma
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
This study will assess the safety of RAD001 when given together with cetuximab and irinotecan
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
- Trial name
- NCT00478634
- Testing
- RAD001, Cetuximab, Irinotecan
- Where
- 16 sites in United States
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Cancer
Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma
This trial will compare the efficacy of docetaxel/carboplatin versus docetaxel/liposomal doxorubicin in pretreated patients with advanced ovarian carcinoma and treatment free-interval of at least six months
- Trial name
- NCT00758732
- Testing
- Docetaxel, Carboplatin, Liposomal doxorubicin
- Where
- 12 sites in Greece
- Volunteers
- 34 people
- Sponsor
- Hellenic Oncology Research Group
Colorectal Neoplasms
Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
Limited agents are optional after standard first and second line treatment for mCRC. Only Regorafenib and Fruquintinib are approved in China. PFS of these targeted drugs are not very long.
- Trial name
- NCT04683965
- Testing
- Pemetrexed, TAS-102, Bevacizumab
- Where
- China
- Volunteers
- 27 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatocellular Carcinoma, Cirrhosis
LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
The purpose of this study is to test the safety and determine the maximum safe dose of an experimental drug called LDE225 (hedgehog inhibitor) in people with liver cancer.
- Trial name
- NCT02151864
- Testing
- LDE225
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Jason K. Sicklick, M.D.
Diabetes Mellitus, Type 2
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
An observational study of electronic patient data to compare diabetes medications and to determine which ones offer the best balance of risks and benefits.
- Trial name
- BESTMED (NCT05161429)
- Testing
- DPP4, GLP-1 receptor agonist, Basal Insulin
- Where
- 5 sites in United States
- Volunteers
- 550,000 people
- Sponsor
- Brigham and Women's Hospital
Colon Cancer, Rectal Cancer
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects.
- Trial name
- NCT01347645
- Testing
- FOLFIRI, E7820
- Where
- 38 sites in United States, Argentina and 4 more
- Volunteers
- 82 people
- Sponsor
- Eisai Inc.
Postpartum Hemorrhage, Second Line Management
Surgical Management of Postpartum Haemorrhage Without Embolization
Postpartum haemorrhage is the main cause of maternal mortality. The aim of investigators' study was to evaluate the practice of hemostatic surgery (arterial ligation, uterine compression or hysterectomy) when the embolization of…
- Conditions
- Postpartum Hemorrhage, Second Line Management, Uterine Arteries Embolization, Surgical Management of Haemorrhage
- Trial name
- NCT03517800
- Testing
- Arterial embolization and/or surgical management.
- Where
- France
- Volunteers
- 716 people
- Sponsor
- University Hospital, Montpellier
Ovarian Cancer
CT-2106 for the Second Line Treatment of Ovarian Cancer
The purpose of this sudy is to determine the response rate of CT-2106 in patients with advanced ovarian cancer who have failed one prior platinum and taxane based regimen.
- Trial name
- NCT00291837
- Testing
- CT-2106
- Where
- 7 sites in France, Italy and 1 more
- Volunteers
- 40 people
- Sponsor
- CTI BioPharma
Metastatic Gastric Cancer
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
To evaluate safety and response rate of durvalumab/tremelimumab in combination with paclitaxel in patients with metastatic gastric cancers who fail a first-line chemotherapy
- Trial name
- NCT03751761
- Testing
- durvalumab, tremelimumab, paclitaxel
- Where
- South Korea
- Volunteers
- 58 people
- Sponsor
- Asan Medical Center
Advanced Biliary Tract Cancers
Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers
To verify the role of nab-paclitaxel in second or later-line treatment in advanced biliary tract cancers, the investigators designed a prospective, exploratory, single arm,single center phase II trial, to investigate the efficacy…
- Trial name
- NCT04111380
- Testing
- cisplatin and nab-paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Provincial People's Hospital
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
The main purpose of this study was to evaluate the safety and pharmacokinetics of administering various dose regimens of ramucirumab in participants with advanced gastric cancer whose disease has progressed during or following…
- Trial name
- NCT02443883
- Testing
- Ramucirumab
- Where
- 45 sites in United States, Argentina and 10 more
- Volunteers
- 164 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to show that tislelizumab will improve overall survival in participants with Stage IIIB or IV non-small cell lung cancer when compared to docetaxel in second or third-line treatment setting.
- Trial name
- RATIONALE-303 (NCT03358875)
- Testing
- Tislelizumab, Docetaxel
- Where
- 121 sites in Brazil, Bulgaria and 8 more
- Volunteers
- 805 people
- Sponsor
- BeiGene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.